EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Keloids - Pipeline Review, H2 2016

  • ID: 4030251
  • Report
  • December 2016
  • 53 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • FirstString Research Inc
  • RXi Pharmaceuticals Corp
  • Topadur Pharma AG
  • Tumorend LLC
  • viDA Therapeutics Inc
  • Yuhan Corp
  • MORE
Keloids - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Keloids - Pipeline Review, H2 2016, provides an overview of the Keloids (Keloids) pipeline landscape.

Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroid, radiation, surgical removal and silicone gel or patches.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Keloids - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Keloids (Keloids), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keloids (Keloids) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Keloids (Keloids) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Keloids (Keloids).
- The pipeline guide reviews pipeline therapeutics for Keloids (Keloids) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keloids (Keloids) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keloids (Keloids) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keloids (Keloids)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keloids (Keloids).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keloids (Keloids) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • FirstString Research Inc
  • RXi Pharmaceuticals Corp
  • Topadur Pharma AG
  • Tumorend LLC
  • viDA Therapeutics Inc
  • Yuhan Corp
  • MORE
Introduction

Keloids Overview

Therapeutics Development

Pipeline Products for Keloids - Overview

Pipeline Products for Keloids - Comparative Analysis

Keloids - Therapeutics under Development by Companies

Keloids - Therapeutics under Investigation by Universities/Institutes

Keloids - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Keloids - Products under Development by Companies

Keloids - Products under Investigation by Universities/Institutes

Keloids - Companies Involved in Therapeutics Development

FirstString Research Inc

RXi Pharmaceuticals Corp

Topadur Pharma AG

Tumorend LLC

viDA Therapeutics Inc

Yuhan Corp

Keloids - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

CM-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granexin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

koebnerisin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

psoriasin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXI-109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOPN-44 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

V-2248 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTI-3000 Series - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-siRNA1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Keloids - Dormant Projects

Keloids - Discontinued Products

Keloids - Product Development Milestones

Featured News & Press Releases

Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology

Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study

Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders

Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period

Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision

Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109

Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Keloids, H2 2016

Number of Products under Development for Keloids - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Keloids - Pipeline by FirstString Research Inc, H2 2016

Keloids - Pipeline by RXi Pharmaceuticals Corp, H2 2016

Keloids - Pipeline by Topadur Pharma AG, H2 2016

Keloids - Pipeline by Tumorend LLC, H2 2016

Keloids - Pipeline by viDA Therapeutics Inc, H2 2016

Keloids - Pipeline by Yuhan Corp, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Keloids - Dormant Projects, H2 2016

Keloids - Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for Keloids, H2 2016

Number of Products under Development for Keloids - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 4
  • FirstString Research Inc
  • RXi Pharmaceuticals Corp
  • Topadur Pharma AG
  • Tumorend LLC
  • viDA Therapeutics Inc
  • Yuhan Corp
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll